Cargando…
Eruptive basal cell carcinoma and lenalidomide: rising awareness among dermatologists
Because of its higher level of safety compared to its parent medicine, thalidomide, lenalidomide (L) is chosen for the treatment of multiple myeloma. We report a patient who, within a month of using L, developed more than 10 basal cell carcinomas.
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
PAGEPress Publications, Pavia, Italy
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10099294/ https://www.ncbi.nlm.nih.gov/pubmed/37063400 http://dx.doi.org/10.4081/dr.2022.9534 |